Posted by Michael Wonder on 05 Nov 2017
Bausch & Lomb and Nicox announce FDA approval of Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%
2 November 2017 - Valeant Pharmaceuticals' wholly owned subsidiary, Bausch & Lomb and Nicox today announced that the U.S. FDA has approved the new drug application for Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%).
Vyzulta, the first prostaglandin analog with one of its metabolites being nitric oxide, is indicated for the reduction of intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.
